September 2023 in “PubMed” Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
January 2026 in “Dermatologic Therapy” Photobiomodulation therapy effectively promotes hair regrowth and improves quality of life in alopecia areata without side effects.
1 citations
,
August 1983 in “PubMed” CVP therapy showed moderate success in treating advanced non-Hodgkin's lymphoma, but more intensive treatment is needed for better outcomes.
November 2024 in “Journal of the European Academy of Dermatology and Venereology” Long-term baricitinib treatment can lead to significant scalp hair regrowth in patients initially showing only eyebrow or eyelash regrowth.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Mini pulse corticosteroid therapy with oral dexamethasone is effective and has fewer side effects for treating extensive alopecia areata.
June 2023 in “Dermatology and Therapy” Using fractional CO2 laser with halometasone cream works better for chronic hand eczema than just the cream, improving symptoms and quality of life with fewer relapses.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib shows promise in improving frontal fibrosing alopecia symptoms.
81 citations
,
August 2011 in “Journal of The American Academy of Dermatology” Latanoprost 0.1% may effectively treat hair loss.
November 2001 in “Oncology Times” The committee decided not to approve the drug due to low effectiveness and high risks.
14 citations
,
January 2015 in “Annals of dermatology/Annals of Dermatology” Corticosteroid pulse therapy is more effective for severe alopecia areata than combination therapy.
1 citations
,
November 2023 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib helps with early hair regrowth in people with alopecia areata.
July 2018 in “International Journal of Research in Medical Sciences” Platelet rich plasma was slightly more effective than no treatment for hair loss in alopecia areata patients.
1 citations
,
December 2024 in “Journal of Orthopaedic Research®” Aromoline and DRD4 are potential targets for osteoarthritis treatment.
September 2009 in “European Urology Supplements” IGRT resulted in lower acute toxicity for stage III prostate cancer patients.
January 2024 in “Wiadomości Lekarskie” Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.
January 2002 in “Journal of Clinical Dermatology” A single dose of Platelet Rich Plasma effectively reduces symptoms of early knee osteoarthritis.
February 2025 in “PubMed” CS12192 effectively treats alopecia areata with better safety than current options.
May 2024 in “Journal of the Egyptian Womenʼs Dermatologic Society” Diphenylcyclopropenone is effective and safe for treating severe alopecia areata in children, with maintenance therapy reducing relapse risk.
34 citations
,
August 2002 in “British Journal of Dermatology” ALA-PDT is effective and safe for chronic X-ray dermatitis, providing complete or partial remission.
June 2023 in “British journal of dermatology/British journal of dermatology, Supplement” Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.
May 2024 in “International journal of medicine and psychology.” Transcranial electrical stimulation with bisphosphonates helps maintain bone collagen better than bisphosphonates alone.
October 2013 in “Revue de Chirurgie Orthopédique et Traumatologique”
1 citations
,
April 2019 in “Journal of Investigative Dermatology” Dupilumab is effective and safe for treating moderate-to-severe atopic dermatitis in adolescents.
12 citations
,
January 2006 in “Journal of Dermatological Treatment” Topical 1% sildenafil is not recommended for treating alopecia areata in children.
November 2023 in “SKIN The Journal of Cutaneous Medicine”
81 citations
,
February 2000 in “Anti-cancer drugs” Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.
October 2004 in “Australian Prescriber” Agalsidase alfa helps treat Fabry's disease but needs more research for long-term benefits.
August 2003 in “Oncology Times” The trial on testosterone replacement therapy in older men faced concerns due to prostate cancer risk.